Last reviewed · How we verify
Nitroglycerin infusion
Nitroglycerin is a nitrate vasodilator that releases nitric oxide to relax vascular smooth muscle and dilate blood vessels.
Nitroglycerin is a nitrate vasodilator that releases nitric oxide to relax vascular smooth muscle and dilate blood vessels. Used for Acute coronary syndrome and angina pectoris, Acute decompensated heart failure with pulmonary edema, Hypertensive emergency.
At a glance
| Generic name | Nitroglycerin infusion |
|---|---|
| Also known as | Millisrol |
| Sponsor | Tri-Service General Hospital |
| Drug class | Nitrate vasodilator |
| Target | Soluble guanylate cyclase (via nitric oxide) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nitroglycerin is metabolized to nitric oxide, which activates guanylate cyclase and increases cyclic GMP levels in vascular smooth muscle cells, leading to vasodilation. This reduces preload and afterload on the heart, decreasing myocardial oxygen demand. The drug preferentially dilates large epicardial coronary arteries and collateral vessels, improving coronary blood flow.
Approved indications
- Acute angina pectoris
- Congestive heart failure with pulmonary edema
- Hypertensive crisis
- Perioperative hypertension
Common side effects
- Headache
- Hypotension
- Tachycardia
- Dizziness
- Flushing
- Methemoglobinemia (with prolonged use)
Key clinical trials
- Evaluating the Effects of Nitroglycerin on Heart Function and Urinary Output in Patients With Acute Heart Failure (PHASE4)
- Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy (NA)
- Optimized Strict Fluid Management Helps Improve Endpoints After Liver Dissection (NA)
- Postprocedural Contrast Mediated FFR Plus Intracoronary Infusion of Nitroglycerin in Multivessel Patients (PROMETEUS TRIAL) (NA)
- Comparison Between the Use of Phentolamine Versus Glyceryl Trinitrate for Their Effect on Renal Function in Pre-eclampsia Patients in ICU (PHASE4)
- Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias (PHASE2)
- : Vascular Function in Health and Disease (PHASE1)
- Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nitroglycerin infusion CI brief — competitive landscape report
- Nitroglycerin infusion updates RSS · CI watch RSS
- Tri-Service General Hospital portfolio CI